Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
A US company was accused of exaggerating its mining experience in a key mineral deal with Congo

A US company was accused of exaggerating its mining experience in a key mineral deal with Congo

金十金十2026/04/21 08:07
Show original
Golden Ten Data reported on April 21 that, according to Reuters, a U.S. company that played a central role in the Trump administration’s push to secure critical minerals from Congo exaggerated its mining experience. In March of this year, Virtus acquired a mine from shareholders of Chemaf Mining Company for $30 million. The company claimed on its website that it had experience in Congo due to its operation of a copper and cobalt processing plant. However, Reuters found that Virtus did not acquire the plant. According to company documents, court records related to disputes over the plant’s sale, and five sources with direct knowledge of the matter, the plant has been idle since 2012. The acquisition of the Chemaf mine marks the first tangible investment under the strategic minerals partnership framework signed last year between the U.S. and the Democratic Republic of Congo (DRC). Washington agreed to help Congo attract U.S. investment into the country’s mining sector in exchange for priority access to critical minerals.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD

Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.

智通财经2026/09/21 07:16

Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).

智通财经2026/09/21 07:11

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11